Letrozolo Tecnigen

Letrozole, the active ingredient in Letrozolo Tecnigen, is an aromatase inhibitor presented as a tablet for oral use. It is employed to treat hormone receptor‑positive breast cancer in postmenopausal women by lowering estrogen levels that can stimulate tumor growth.

GNH USA supplies Letrozolo Tecnigen as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable sourcing for clinical and retail settings. All shipments are accompanied by full documentation to facilitate regulatory approval in destination markets.

Letrozole is used in the management of hormone‑dependent breast cancer, targeting estrogen‑driven tumor growth.

- Hormone receptor‑positive breast cancer (postmenopausal): reduces estrogen production to inhibit tumor progression. - Adjuvant therapy for early‑stage breast cancer: improves disease‑free survival after surgery. - Metastatic breast cancer (postmenopausal): helps control disease spread by lowering circulating estrogen levels.

Letrozole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes - Joint and muscle pain - Fatigue - Nausea - Headache - Increased sweating

Serious or Rare Side Effects: - Severe osteoporosis or bone fractures - Liver enzyme elevations or hepatitis - Deep vein thrombosis and pulmonary embolism - Anaphylactic or severe allergic reactions - Cardiac arrhythmias such as QT prolongation

When prescribing Letrozole, clinicians should consider several safety measures to minimize risks.

- Monitor bone mineral density: assess risk of osteoporosis and consider calcium/vitamin D supplementation. - Evaluate liver function: perform baseline and periodic hepatic enzyme tests. - Assess cardiovascular risk: watch for signs of thromboembolic events. - Avoid use in premenopausal women: drug is ineffective and may cause ovarian stimulation. - Review concomitant medications: check for interactions that may alter letrozole exposure. - Store at ambient temperature: keep tablets in original packaging, protect from moisture and direct light.

Letrozole’s metabolism and pharmacodynamics can be affected by other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce letrozole plasma levels. - Estrogen‑containing hormone therapy: counteracts the intended estrogen suppression. - Tamoxifen: antagonistic effect on estrogen pathways, diminishing therapeutic benefit.

Moderate Interactions (Monitor Closely): - CYP2A6 or CYP3A4 inhibitors (e.g., fluvoxamine, ketoconazole): may increase letrozole exposure. - Warfarin: potential alteration of INR, requiring closer coagulation monitoring. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): possible modest effect on metabolism.